01GeneDx Holdings Corp. (WGS) will report Q3 2026 earnings on October 27, 2026 after market close.
02Analysts expect Q3 earnings per share of $0.07, compared to $0.00 in the prior year quarter.
03Revenue is projected at $122.8M, representing year-over-year growth from the prior year period.
04The stock trades at $61.24 with a market capitalization of $4.5 billion as of the article date.
05Recent earnings history shows volatility, with Q2 2026 beating estimates by 105.3% and Q1 2026 missing by 833.3%.
Earnings Results
GeneDx Holdings Corp. (NASDAQ:WGS) is scheduled to report its Q3 earnings results on October 27, 2026 after market close.
Analysts expect the Healthcare company to report earnings per share of $0.07, above the $0.00 reported in the same quarter last year. Revenue is expected to come in at $122.8M, up from a year ago.
Company Overview
The stock currently trades at $61.24 with a market capitalization of $4.5B.
Ahead of GeneDx Holdings Corp.'s earnings report, investors are watching several key metrics beyond the headline EPS number. Revenue growth, margin trends, and forward guidance will likely carry more weight than a single quarter's earnings figure in determining the stock's direction after the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking GeneDx Holdings Corp. should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.